For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Phurrough	Gozansky	Heseltine	Levine	Massey	McDonough	Reddy	Sedrakyan	Steinbrook	Dubois	Puklin	Voting Member Average	Overall Average
2 How confident are you that there is adequate evidence to determine whether or not DME management using intravitreal targeted anti-VEGF treatment improves patient health outcomes compared to DME management without intravitreal targeted anti-VEGF treatment?													
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence													
	4	4	5	4	3	4	4	4	5	4	5	**4.00**	**4.18**

		Phurrough	Gozansky	Heseltine	Levine	Massey	McDonough	Reddy	Sedrakyan	Steinbrook	Dubois	Puklin	Voting Member Average	Overall Average
3	*If the result of Question 2 is at least intermediate (mean vote ≥ 2.5), how confident are you that there is adequate evidence to conclude that DME management using intravitreal targeted anti-VEGF treatment improves patient health outcomes compared to DME management without intravitreal targeted anti-VEGF treatment?*													
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence	4	3	4	4	4	4	4	3	4	4	5	**3.75**	**3.91**

		Phurrough	Gozansky	Heseltine	Levine	Massey	McDonough	Reddy	Sedrakyan	Steinbrook	Dubois	Puklin	Voting Member Average	Overall Average
4	*If the result of Question 3 is at least intermediate (mean vote ≥ 2.5), how confident are you that there is also adequate evidence to determine whether or not there are clinically meaningful differences in health outcomes among the available intravitreal targeted anti-VEGF treatments for the management of DME?*													
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence	3	2	1	1	3	3	2	2	2	3	3	2.13	2.27

		Phurrough	Gozansky	Heseltine	Levine	Massey	McDonough	Reddy	Sedrakyan	Steinbrook	Dubois	Puklin	Voting Member Average	Overall Average
5	*If the result of Question 4 is at least intermediate (mean vote ≥ 2.5), how confident are you that there is adequate evidence to conclude that there are clinically meaningful differences in the health outcomes when comparing the following available intravitreal targeted anti-VEGF treatments?*													
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence													
	a. Ranibizumab vs pegatanib													
	b. Bevacizumab vs. pegatanib													
	c. Ranibizumab vs bevacizumab													

The mean vote was less than 2.5 so the panel members did not vote on question 5.

		Phurrough	Gozansky	Heseltine	Levine	Massey	McDonough	Reddy	Sedrakyan	Steinbrook	Dubois	Puklin	Voting Member Average	Overall Average
6	*In the general Medicare population:*													
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence													
	a. Medicare beneficiaries?	4	4	5	4	4	4	4	4	4	4	5	4.13	4.18
	b. Community-based settings?	3	4	4	4	4	3	4	2	4	4	5	3.50	3.73